Hepatitis B surface antigen (HBsAg) levels in the prediction of spontaneous HBsAg seroclearance
Yi‐Cheng Chen – 10 August 2012
Practice guidelines on NAFLD
Melissa Palmer – 10 August 2012
Spontaneous clearance of hepatitis C virus in an interleukin 28B favorable genotype highly prevalent area
Chao‐Hung Hung, Kuo‐Chin Chang, Sheng‐Nan Lu, Jing‐Houng Wang, Chien‐Hung Chen, Chuan‐Mo Lee, Tsung‐Hui Hu – 10 August 2012
Yes‐associated protein regulates the hepatic response after bile duct ligation
Haibo Bai, Nailing Zhang, Yang Xu, Qian Chen, Mehtab Khan, James J. Potter, Suresh K. Nayar, Toby Cornish, Gianfranco Alpini, Steven Bronk, Duojia Pan, Robert A. Anders – 8 August 2012 – Human chronic cholestatic liver diseases are characterized by cholangiocyte proliferation, hepatocyte injury, and fibrosis. Yes‐associated protein (YAP), the effector of the Hippo tumor‐suppressor pathway, has been shown to play a critical role in promoting cholangiocyte and hepatocyte proliferation and survival during embryonic liver development and hepatocellular carcinogenesis.
Quality of life after living donor liver transplantation: What we have learned and how we can do better
Leona Kim‐Schluger, Sander Florman – 6 August 2012
Risk of cytomegalovirus disease in high‐risk liver transplant recipients on valganciclovir prophylaxis: A systematic review and meta‐analysis
Andre C. Kalil, Cezarina Mindru, Jean F. Botha, Wendy J. Grant, David F. Mercer, Marco A. Olivera, Megan A. McCartan, Timothy M. McCashland, Alan N. Langnas, Diana F. Florescu – 6 August 2012 – Valganciclovir (VGC) was approved by the Food and Drug Administration in 2004 as cytomegalovirus (CMV) prophylaxis except for liver transplant recipients because of their high incidence of CMV disease with this drug. However, surveys have shown its common off‐label use for CMV prophylaxis in liver transplant recipients.
Burden of de novo malignancy in the liver transplant recipient
Natasha Chandok, Kymberly D. Watt – 6 August 2012 – Recipients of liver transplantation (LT) have a higher overall risk (2‐3 times on average) of developing de novo malignancies than the general population, with standardized incidence ratios ranging from 1.0 for breast and prostate cancers to 3‐4 for colon cancer and up to 12 for esophageal and oropharyngeal cancers.
Monitoring alcohol use on the liver transplant wait list: Therapeutic and practical issues
Andrea F. DiMartini, Mary Amanda Dew – 6 August 2012
A functional screening identifies five micrornas controlling glypican‐3: role of mir‐1271 down‐regulation in hepatocellular carcinoma
Marion Maurel, Sandra Jalvy, Yannick Ladeiro, Chantal Combe, Laetitia Vachet, Francis Sagliocco, Paulette Bioulac‐Sage, Vincent Pitard, Hélène Jacquemin‐Sablon, Jessica Zucman‐Rossi, Benoît Laloo, Christophe F. Grosset – 3 August 2012 – Hepatocellular carcinoma (HCC) is the major primary liver cancer. Glypican‐3 (GPC3), one of the most abnormally expressed genes in HCC, participates in liver carcinogenesis.